Imperial College London

DrRichardNicholas

Faculty of MedicineDepartment of Brain Sciences

Professor of Practice (Neurology)
 
 
 
//

Contact

 

r.nicholas

 
 
//

Location

 

12L12CLab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Bermel:2016,
author = {Bermel, R and Comi, G and Eralinna, J-P and Leist, TP and Nicholas, R and Oreja-Guevara, C and Siva, A and Van, Wijmeersch B and Wiendl, H and Bernasconi, C and Buffels, R and Csoboth, C and Han, J and Musch, B and Vermersch, P},
pages = {615--616},
publisher = {SAGE PUBLICATIONS LTD},
title = {Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment},
url = {http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383267202379&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202},
year = {2016}
}

RIS format (EndNote, RefMan)

TY  - CPAPER
AU - Bermel,R
AU - Comi,G
AU - Eralinna,J-P
AU - Leist,TP
AU - Nicholas,R
AU - Oreja-Guevara,C
AU - Siva,A
AU - Van,Wijmeersch B
AU - Wiendl,H
AU - Bernasconi,C
AU - Buffels,R
AU - Csoboth,C
AU - Han,J
AU - Musch,B
AU - Vermersch,P
EP - 616
PB - SAGE PUBLICATIONS LTD
PY - 2016///
SN - 1352-4585
SP - 615
TI - Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383267202379&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
ER -